Olorinab - Pfizer
Alternative Names: APD-371Latest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals
- Developer Pfizer
- Class Analgesics; Pyrazoles; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome; Pain
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 04 Feb 2022 Arena pharmaceuticals has patent protection for olorinab in USA, China, Japan, Canada, India, Russia, South Korea and Australia, Europe, Venezuela, and Brazil (Arena pharmaceuticals form 10-k, February 2022)
- 03 Oct 2021 Efficacy and safety data from phase IIb CAPTIVATE trial in Pain presented at 29th United European Gastroenterology Week (UEGW-2021)